United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - aprepitant (unii: 1nf15yr6uy) (aprepitant - unii:1nf15yr6uy) - aprepitant 1 kg in 1 kg

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - aprepitant -

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - fosaprepitant dimeglumine (unii: d35fm8t64x) (aprepitant - unii:1nf15yr6uy) - fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: - acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (hec) including high-dose cisplatin. - delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (mec). limitations of use - fosaprepitant for injection has not been studied for the treatment of established nausea and vomiting. pediatric use information is approved for merck sharp & dohme corp., a subsidiary of merck & co., inc.'s emend (fosaprepitant) for injection. however, due to merck sharp & dohme corp., a subsidiary of merck & co., inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information. fosaprepitant for injection is contraindicated in patients: - who are hypersensitive to any component of the product. hypersensitivity reactions including anaphylactic reaction

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - fosaprepitant dimeglumine (unii: d35fm8t64x) (aprepitant - unii:1nf15yr6uy) - fosaprepitant for injection is a substance p/neurokinin-1 (nk1 ) receptor antagonist, indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of (1): -   acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (hec) including high-dose cisplatin. -   delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (mec). limitations of use - fosaprepitant for injection has not been studied for the treatment of established nausea and vomiting. fosaprepitant is contraindicated in patients: - who are hypersensitive to any component of the product. hypersensitivity reactions including anaphylactic reactions, flushing, erythema, and dyspnea have been reported [see warnings and precautions (5.2), adverse reactions (6.2) ]. - taking pimozide. inhibition of cyp3a4 by aprepitant, the active moiety, could result in elevated plasma concentrations of this drug, which is a cyp3a4 substrate, potentially causing serious or life-threatening reactions, such as qt prolongation, a known adverse reaction of pimozide [see warnings and precautions (5.1) ]. risk summary there are insufficient data on use of fosaprepitant in pregnant women to inform a drug associated risk. in animal reproduction studies, no adverse developmental effects were observed in rats or rabbits exposed during the period of organogenesis to systemic drug levels (auc) approximately equivalent to the exposure at the recommended human dose (rhd) of 150 mg [see data ]. the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data animal data: in embryofetal development studies in rats and rabbits, aprepitant was administered during the period of organogenesis at oral doses up to 1000 mg/kg twice daily (rats) and up to the maximum tolerated dose of 25 mg/kg/day (rabbits). no embryofetal lethality or malformations were observed at any dose level in either species. the exposures (auc) in pregnant rats at 1000 mg/kg twice daily and in pregnant rabbits at 25 mg/kg/day were approximately equivalent to the exposure at the rhd of 150 mg. aprepitant crosses the placenta in rats and rabbits. risk summary lactation studies have not been conducted to assess the presence of aprepitant in human milk, the effects on the breastfed infant, or the effects on milk production. aprepitant is present in rat milk. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for fosaprepitant and any potential adverse effects on the breastfed infant from fosaprepitant or from the underlying maternal condition. contraception upon administration of fosaprepitant, the efficacy of hormonal contraceptives may be reduced. advise females of reproductive potential using hormonal contraceptives to use an effective alternative or back-up non-hormonal contraceptive (such as condoms and spermicides) during treatment with fosaprepitant and for 1 month following the last dose [see drug interactions (7.1), clinical pharmacology (12.3) ]. the safety and effectiveness of a single dose and a 3-day regimen of  fosaprepitant for injection have been established in pediatric patients 6 months to 17 years for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of hec and mec. use of fosaprepitant for injection in this age group is supported by evidence from adequate and well-controlled studies of fosaprepitant for injection in adults, with additional safety, efficacy and pharmacokinetic data in pediatric patients 6 months to 17 years. efficacy and safety were also supported by data from an adequate and well-controlled study of a 3-day oral aprepitant regimen in pediatric patients 6 months to 17 years.  see the full prescribing information for emend capsules for complete clinical information regarding studies performed with oral aprepitant. adverse reactions were similar to those reported in adult patients. [see dosage and administration (2.2), adverse reactions (6.1), clinical pharmacology (12.3) ]. the safety and effectiveness of fosaprepitant for the prevention of nausea and vomiting associated with hec or mec have not been established in patients less than 6 months of age.   juvenile animal toxicity data in juvenile dogs treated with fosaprepitant, changes in reproductive organs were observed. in juvenile rats treated with aprepitant, slight changes in sexual maturation were observed without an effect on reproduction. no effects on neurobehavior, sensory and motor function, or learning and memory were observed in rats. in a toxicity study in juvenile dogs treated with fosaprepitant from postnatal day 14 (equivalent to a newborn human) to day 42 (approximately equivalent to a 2 year old human), decreased testicular weight and leydig cell size were seen in the males at 6 mg/kg/day and increased uterine weight, hypertrophy of the uterus and cervix, and edema of vaginal tissues were seen in females from 4 mg/kg/day. a study was also conducted in young rats to evaluate the effects of aprepitant on growth and on neurobehavioral and sexual development. rats were treated at oral doses up to the maximum feasible dose of 1000 mg/kg twice daily (providing exposure in male and female rats lower than the exposure at the recommended pediatric human dose) from the early postnatal period (postnatal day 10 (equivalent to a newborn human) through postnatal day 58 (approximately equivalent to a 15 year old human)). slight changes in the onset of sexual maturation were observed in female and male rats; however, there were no effects on mating, fertility, embryonic-fetal survival, or histomorphology of the reproductive organs. there were no effects in neurobehavioral tests of sensory function, motor function, and learning and memory. additional pediatric use information is approved for merck sharp & dohme llc's emend (fosaprepitant) for injection. however, due to merck sharp & dohme llc's marketing exclusivity rights, this drug product is not labeled with that information. of the 1649 adult cancer patients treated with intravenous fosaprepitant in hec and mec clinical studies, 27% were aged 65 and over, while 5% were aged 75 and over. other reported clinical experience with fosaprepitant has not identified differences in responses between elderly and younger patients. in general, use caution when dosing elderly patients as they have a greater frequency of decreased hepatic, renal or cardiac function and concomitant disease or other drug therapy [see clinical pharmacology (12.3) ].   the pharmacokinetics of aprepitant in patients with mild and moderate hepatic impairment were similar to those of healthy subjects with normal hepatic function. no dosage adjustment is necessary for patients with mild to moderate hepatic impairment (child-pugh score 5 to 9). there are no clinical or pharmacokinetic data in patients with severe hepatic impairment (child-pugh score greater than 9). therefore, additional monitoring for adverse reactions in these patients may be warranted when fosaprepitant is administered [see clinical pharmacology (12.3) ].  

United States - English - NLM (National Library of Medicine)

torrent pharmaceuticals limited - aprepitant (unii: 1nf15yr6uy) (aprepitant - unii:1nf15yr6uy) - aprepitant capsules, in combination with other antiemetic agents, is indicated in patients 12 years of age and older for the prevention of: - acute and delayed nausea and vomiting associted with initial and repeat courses of highly emetogenic cancer chemotherapy (hec) including high-dose cisplatin. - nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (mec). aprepitant capsules are indicated in adults for the prevention of postoperative nausea and vomiting. - aprepitant has not been studied for the treatment of established nausea and vomiting. - chronic continuous administration of aprepitant is not recommended because it has not been studied, and because the drug interaction profile may change during chronic continuous use. aprepitant is contraindicated in patients: • who are hypersensitive to any component of the product. hypersensitivity reactions including anaphylactic reactions have been reported [see adverse reactions (6.2)] .  • taking pimozide. inhibition of cyp3a4 by aprepitant could result in elevated plasma concentrations of this drug which is a cyp3a4 substrate, potentially causing serious or life-threatening reactions, such as qt prolongation, a known adverse reaction of pimozide [see warnings and precautions (5.1)] . risk summary there are insufficient data on use of aprepitant in pregnant women to inform a drug associated risk. in animal reproduction studies, no adverse developmental effects were observed in rats or rabbits exposed during the period of organogenesis to systemic drug levels (auc) approximately 1.5 times the adult human exposure at the 125-mg/80-mg/ 80-mg aprepitant regimen [see data] . the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.  data animal data in embryofetal development studies in rats and rabbits, aprepitant was administered during the period of organogenesis at oral doses up to 1,000 mg/kg twice daily in rats and up to the maximum tolerated dose of 25 mg/kg/day in rabbits. no embryofetal lethality or malformations were observed at any dose level in either species. the exposures (auc) in pregnant rats at 1,000 mg/kg twice daily and in pregnant rabbits at 125 mg/kg/day were approximately 1.5 times the adult exposure at the 125-mg/80mg/80-mg aprepitant regimen. aprepitant crosses the placenta in rats and rabbits. risk summary lactation studies have not been conducted to assess the presence of aprepitant in human milk, the effects on the breastfed infant, or the effects on milk production. aprepitant is present in rat milk. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for aprepitant and any potential adverse effects on the breastfed infant from aprepitant or from the underlying maternal condition. contraception upon administration of aprepitant, the efficacy of hormonal contraceptives may be reduced. advise females of reproductive potential using hormonal contraceptives to use an effective alternative or back-up non-hormonal contraceptive (such as condoms and spermicides) during treatment with aprepitant and for 1 month following the last dose [see drug interactions (7.1), clinical pharmacology (12.3)] . prevention of nausea and vomiting associated with hec or mec the safety and effectiveness of aprepitant capsules in pediatric patients 12 years of age and older for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of hec, including high-dose cisplatin, and mec. use of aprepitant in these age groups is supported by evidence from 302 pediatric patients in a randomized, double-blind, active comparator controlled clinical study (n=207 patients aged 6 months to less than 12 years, n=95 patients aged 12 through 17 years). aprepitant was studied in combination with ondansetron with or without dexamethasone (at the discretion of the physician) [see clinical studies (14.3)] . adverse reactions were similar to those reported in adult patients [see adverse reactions (6.1)] . the safety and effectiveness of aprepitant for the prevention of nausea and vomiting associated with hec or mec have not been established in patients less than 6 months. prevention of postoperative nausea and vomiting (ponv) the safety and effectiveness of aprepitant have not been established for the prevention of postoperative nausea and vomiting in pediatric patients. juvenile animal study a study was conducted in young rats to evaluate the effects of aprepitant on growth and on neurobehavioral and sexual development. rats were treated at oral doses up to the maximum feasible dose of 1,000 mg/kg twice daily (providing exposure in male rats lower than the exposure at the recommended pediatric human dose and exposure in female rats equivalent to the pediatric human exposure) from the early postnatal period (postnatal day 10) through postnatal day 58. slight changes in the onset of sexual maturation were observed in female and male rats; however, there were no effects on mating, fertility, embryonic-fetal survival, or histomorphology of the reproductive organs. there were no effects in neurobehavioral tests of sensory function, motor function, and learning and memory. of the 544 adult cancer patients treated with aprepitant in cinv clinical studies, 31% were aged 65 and over, while 5% were aged 75 and over. of the 1,120 adult cancer patients treated with aprepitant in ponv clinical studies, 7% were aged 65 and over, while 2% were aged 75 and over. other reported clinical experience with aprepitant has not identified differences in responses between elderly and younger patients. in general, use caution when dosing elderly patients as they have a greater frequency of decreased hepatic, renal or cardiac function and concomitant disease or other drug therapy [see clinical pharmacology (12.3)] . the pharmacokinetics of aprepitant in patients with severe renal impairment and those with end stage renal disease (esrd) requiring hemodialysis were similar to those of healthy subjects with normal renal function. no dosage adjustment is necessary for patients with any degree of renal impairment or for patients with esrd undergoing hemodialysis.  the pharmacokinetics of aprepitant in patients with mild and moderate hepatic impairment were similar to those of healthy subjects with normal hepatic function. no dosage adjustment is necessary for patients with mild to moderate hepatic impairment (child-pugh score 5 to 9). there are no clinical or pharmacokinetic data in patients with severe hepatic impairment (child-pugh score greater than 9). therefore, additional monitoring for adverse reactions in these patients may be warranted when aprepitant is administered [see clinical pharmacology (12.3)] .

United States - English - NLM (National Library of Medicine)

eugia us llc - fosaprepitant dimeglumine (unii: d35fm8t64x) (aprepitant - unii:1nf15yr6uy) - fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: - acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (hec) including high-dose cisplatin. - delayed  nausea  and  vomiting  associated  with  initial  and  repeat  courses  of  moderately emetogenic cancer chemotherapy (mec). limitations of use - fosaprepitant has not been studied for the treatment of established nausea and vomiting. fosaprepitant is contraindicated in patients: - who are hypersensitive to any component of the product. hypersensitivity reactions including anaphylactic reactions, flushing, erythema, and dyspnea have been reported [see warnings and precautions (5.2), adverse reactions (6.2)]. - taking pimozide. inhibition of cyp3a4 by aprepitant, the active moiety, could result in elevated plasma concentrations of this drug, which is a cyp3a4 substrate, potentially causing serious or life-threatening reactions, such as qt prolongation, a known adverse reaction of pimozide [see warnings and precautions (5.1)]. risk summary there are insufficient data on use of fosaprepitant in pregnant women to inform a drug associated risk. in animal reproduction studies, no adverse developmental effects were observed in rats or rabbits exposed during the period of organogenesis to systemic drug levels (auc) approximately equivalent to the exposure at the recommended human dose (rhd) of 150 mg [see data]. the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data animal data in embryofetal development studies in rats and rabbits, aprepitant was administered during the period of organogenesis at oral doses up to 1,000 mg/kg twice daily (rats) and up to the maximum tolerated dose of 25 mg/kg/day (rabbits). no embryofetal lethality or malformations were observed at any dose level in either species. the exposures (auc) in pregnant rats at 1,000 mg/kg twice daily and in pregnant rabbits at 25 mg/kg/day were approximately equivalent to the exposure at the rhd of 150 mg. aprepitant crosses the placenta in rats and rabbits. risk summary lactation studies have not been conducted to assess the presence of aprepitant in human milk, the effects on the breastfed infant, or the effects on milk production. aprepitant is present in rat milk. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for fosaprepitant and any potential adverse effects on the breastfed infant from fosaprepitant or from the underlying maternal condition. contraception upon administration of fosaprepitant, the efficacy of hormonal contraceptives may be reduced. advise females of reproductive potential using hormonal contraceptives to use an effective alternative or back-up non-hormonal contraceptive (such as condoms and spermicides) during treatment with fosaprepitant and for 1 month following the last dose [see drug interactions (7.1), clinical pharmacology (12.3)]. the safety and effectiveness of fosaprepitant for the prevention of nausea and vomiting associated with hec or mec have not been established in patients less than 6 months of age. juvenile animal toxicity data in juvenile dogs treated with fosaprepitant, changes in reproductive organs were observed. in juvenile rats treated with aprepitant, slight changes in sexual maturation were observed without an effect on reproduction. no effects on neurobehavior, sensory and motor function, or learning and memory were observed in rats. in a toxicity study in juvenile dogs treated with fosaprepitant from postnatal day 14 (equivalent to a newborn human) to day 42 (approximately equivalent to a 2 year old human), decreased testicular weight and leydig cell size were seen in the males at 6 mg/kg/day and increased uterine weight, hypertrophy of the uterus and cervix, and edema of vaginal tissues were seen in females from 4 mg/kg/day. a study was also conducted in young rats to evaluate the effects of aprepitant on growth and on neurobehavioral and sexual development. rats were treated at oral doses up to the maximum feasible dose of 1,000 mg/kg twice daily from the early postnatal period (postnatal day 10 (equivalent to a newborn human) through postnatal day 58 (approximately equivalent to a 15 year old human)). slight changes in the onset of sexual maturation were observed in female and male rats; however, there were no effects on mating, fertility, embryonic-fetal survival, or histomorphology of the reproductive organs. there were no effects in neurobehavioral tests of sensory function, motor function, and learning and memory. pediatric use information is approved for merck sharp & dohme corp., a subsidiary of merck & co., inc.’s emend (fosaprepitant) for injection. however, due to merck sharp & dohme corp., a subsidiary of merck & co., inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. of the 1,649 adult cancer patients treated with intravenous fosaprepitant in hec and mec clinical studies, 27%  were aged  65 and  over,  while  5%  were  aged  75  and  over. other reported clinical experience with fosaprepitant has not identified differences in responses between elderly and younger patients. in general, use caution when dosing elderly patients as they have a greater frequency of decreased hepatic, renal or cardiac function and concomitant disease or other drug therapy [see clinical pharmacology (12.3)]. the pharmacokinetics of aprepitant in patients with mild and moderate hepatic impairment were similar to those of healthy subjects with normal hepatic function. no dosage adjustment is necessary for patients with mild to moderate hepatic impairment (child-pugh score 5 to 9). there are no clinical or pharmacokinetic data in patients with severe hepatic impairment (child-pugh score greater than 9). therefore, additional monitoring for adverse reactions in these patients may be warranted when fosaprepitant is administered [see clinical pharmacology (12.3)].

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - fosaprepitant dimeglumine (unii: d35fm8t64x) (aprepitant - unii:1nf15yr6uy) - fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: - acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (hec) including high-dose cisplatin. - delayed  nausea  and  vomiting  associated  with  initial  and  repeat  courses  of  moderately emetogenic cancer chemotherapy (mec). limitations of use - fosaprepitant has not been studied for the treatment of established nausea and vomiting. pediatric use information is approved for merck sharp & dohme corp., a subsidiary of merck & co., inc.’s emend (fosaprepitant) for injection. however, due to merck sharp & dohme corp., a subsidiary of merck & co., inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. fosaprepitant is contraindicated in patients: - who are hypersensitive to any component of the product. hypersensitivity reactions including anaphylactic reactions, flushing, eryth

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

eurolab (pty) ltd, south africa - aprepitant - capsules, hard - 250/80 mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

eurolab (pty) ltd, south africa - aprepitant - capsules, hard - 125

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

eurolab (pty) ltd, south africa - aprepitant - capsules, hard - 80 mg